News

The new initiative targets chronic illness and diet-related disease in Oklahoma through SNAP reform, food policy changes, and personal health responsibility ...
A federal judge ruled that recent mass layoffs at the U.S. Department of Health and Human Services were likely unlawful and ...
Oklahoma Governor and U.S. Health Secretary launch "Make Oklahoma Healthy Again" campaign targeting state's poor health ...
Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote.
Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months. FDA’s long-standing accelerated approval […] ...
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.
Earlier this week, two new leaders of the US Food and Drug Administration published a list of priorities for the agency. Both Marty Makary and Vinay Prasad are controversial figures in the science ...
People getting sick from ivermectin — especially as some people take a formulation of the drug used in livestock — has become so frequent that this month the Food and Drug Administration ...
In case you haven't had enough about artificial intelligence, the US Food and Drug Administration is now outsourcing its oversight duties to a large language model (LLM.) This includes reviewing ...
Teens who see social media posts showing cannabis or e-cigarettes, including from friends and influencers, are more likely to ...
Why FDA approval of new HIV prevention drug is a big deal The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV.
The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV. The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday ...